Skip to search formSkip to main contentSkip to account menu

Edivoxetine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?
OBJECTIVE To identify symptoms potentially representative of a noradrenergic symptom cluster as possible predictors of response… 
2016
2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor…
OBJECTIVE Three studies examined whether edivoxetine (a highly selective norepinephrine reuptake inhibitor) had efficacy as… 
2015
2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
Objective: The aim of this analysis was to assess the safety profile of edivoxetine as adjunctive treatment to selective… 
2015
2015
Leveraging BCS in Development: A Case Study.
In this work, we discuss leveraging the Biopharmaceutics Classification System (BCS) in the development of edivoxetine HCl, a… 
Review
2014
Review
2014
A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder
Introduction: The majority of available therapeutics to treat attention-deficit/hyperactivity disorder (ADHD) are formulations of… 
2014
2014
Safety and Tolerability of Edivoxetine for Long-Term Treatment of Major Depressive Disorder in Adult Patients
This 12-month open-label, but dose-blinded extension phase, evaluated the safety and tolerability of flexibly-dosed edivoxetine… 
2013
2013
Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE The purpose of this study was to assess the clinical outcomes from an open label study of edivoxetine, a selective… 
2013
2013
Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table
2013
2013
The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor
To assess the impact of hepatic or renal impairment on the pharmacokinetics (PK) of edivoxetine. Two separate multi-center, open… 
2012
2012
Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder.
OBJECTIVE Edivoxetine (LY2216684) is a selective and potent norepinephrine reuptake inhibitor (NERI). The pharmacokinetics (PK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)